Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BND-22 and Cemiplimab in Solid Tumors
NCT06651593Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2025
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BND-22 in solid tumor, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and adverse events at 1 year. Started Jul 2025; status: recruiting.
02
Drugs
BND-22
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06651593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06651593.